Bluechiip Eyes 2025 Growth Amid Strategic Review and BioLife Partnership

middle.news 2:30pm on Thursday 30th of January, 2025 AEDT • Healthcare Read Story

Bluechiip Eyes 2025 Growth Amid Strategic Review and BioLife Partnership

2:30pm on Thursday 30th of January, 2025 AEDT Key Points Shares suspended pending 2024 audited accounts and Annual Report Strategic Review ongoing with focus on partnerships, refinancing, and potential sale BioLife deal announced in December 2024 seen as key revenue driver Established solid customer base including large pharma and Ivy League institution Read Story

middle. Tap to Read Tap the card to read the full analysis about BCT OPEN ARTICLE